 | |
.jpg) Offices in New Haven, Connecticut | |
| Company type | Subsidiary |
|---|---|
| Nasdaq: ALXN | |
| Industry | Pharmaceutical industry |
| Founded | 1992 |
| Founder | Leonard Bell |
| Headquarters | Boston, Massachusetts, U.S. |
Key people | Leonard Bell (chairman) Ludwig N. Hantson (CEO) |
| Products | Eculizumab (Soliris) Ravulizumab (Ultomiris) Asfotase alfa (Strensiq) Sebelipase alfa (Kanuma) Andexanet alfa (Andexxa) |
| Revenue |  US$6.069 billion (2020) |
 US$603 million (2020) | |
| Total assets | US$18.103 billion (2020) |
| Total equity | US$11.651 billion (2020) |
Number of employees | 2,525 (2020) |
| Parent | AstraZeneca |
| Website | www |
| Footnotes / references [1] | |
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa), used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.[1]
With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.[2]
- ^ a b "Alexion Pharmaceuticals 2020 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
- ^ Thomas, Katie; Abelson, Reed (August 25, 2019). "The $6 Million Drug Claim". The New York Times.